CTRI/2024/04/065411尚未招募Unknown
Evaluation of comedogenicity potential of the Kojigold cream by follicular biopsy test. - NI
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Healthy male and female volunteers aged 18 to 65 with no active dermatological
- •2.Good general and mental health with, in the opinion of the investigator or medically qualified designee with no clinically significant and relevant
- •abnormalities in medical history or upon physical examination
- •3.Subjects who have normal, dry, oily, combination (mixed) type of skin types.
- •4.Fitzpatrick photo type I to IV skin type
- •5.Willingness to participate as evidenced by voluntary written informed consent
排除标准
- •1.Healthy male and female volunteers aged 18 to 65 with no active dermatological
- •2.Good general and mental health with, in the opinion of the investigator or medically qualified designee with no clinically significant and relevant
- •abnormalities in medical history or upon physical examination
- •3.Subjects who have normal, dry, oily, combination (mixed) type of skin types.
- •4.Fitzpatrick photo type I to IV skin type
- •5.Willingness to participate as evidenced by voluntary written informed consent
- •Exclusion Criteria:
- •1.Women who are known to be pregnant or who are intending to become pregnant over the duration of the study
- •2.Women who are breast-feeding
- •3.Any history of significant dermatological diseases or conditions or medical conditions known to alter skin appearance or physiologic response (e.g. diabetes,) which could, in the opinion of the Investigator, preclude topical application of the investigational products and/or interfere with the evaluation of the test site reaction.
- •4.Presence of Acne, TLC more than 10 (Inflammatory & Non-Inflammatory).
- •5.Presence of Acne, TLC more than 10 (Inflammatory & Non-Inflammatory).
- •6.Considered immune compromised.
- •7.History of photosensitivity, & or diseases aggravated or triggered by ultraviolet radiation.
- •8.Participants with dermatographism.
- •9.Currently using any medication which in the opinion of the investigator, may affect the evaluation of the study product, or place the subject at undue risk.
- •10.Use of the following topical or systemic medications: immunosuppressants, antihistamines, nonhormonal anti-inflammatory drugs, and corticosteroids up to 2 weeks before screening visit.
- •11.Oral or topical treatment with vitamin A acid and/or its derivatives up to 1 month before the screening visit
- •12.Intention of being vaccinated during the study period or vaccination within 3 weeks of the screening visit.
- •13.Currently receiving allergy injections, or due to receive an injection within 7 days prior to Visit1, or expects to begin injections during study participation
- •14.Previous history of atopic dermatitis, allergic reactions, irritation or intense discomfort feelings to topical use products, cosmetics, or medication.
- •15.Known or suspected intolerance or hypersensitivity to any of the study materials (or closely related compounds) or any of their stated ingredients including any component of the study product.
- •16.History of sensitization in a previous patch study
- •17.Participation in another clinical study (including cosmetic studies) or receipt of an investigational drug within 30days of the screening visit
- •18.Recent history (within the last years) of alcohol or other substance abuse
研究者
相似试验
已完成
Unknown
A study to evaluate blackheads and white headsCTRI/2023/04/052018Sami Sabinsa Group Ltd13
已完成
不适用
A study to check comedogenic potential of cosmetic skin care for 4 weeksCTRI/2023/01/049199ITC Life Sciences & Technology Centre27
尚未招募
不适用
Safety and Efficacy assessment of Product on skiCTRI/2022/05/042840Sun Pharmaceutical Industries Limited
尚未招募
不适用
Safety and Efficacy assessment of Product on skiCTRI/2022/04/042257Sun Pharmaceutical Industries Limited
已完成
不适用
Effect on skin condition and horny grains by continuous use of apricot kernel oil and combined use of massageHealthy adult femaleJPRN-UMIN000044982Japan Clinical Trial Association27